Form 4: Galera Therapeutics Executive Acquires 2,000,000 Stock Options
SEC Form 4 Filing
Joel F. Sussman, Chief Accounting Officer of Galera Therapeutics, Inc., acquired 2,000,000 stock options on May 1, 2025.
Summary
- On May 1, 2025, Joel F. Sussman, the Chief Accounting Officer of Galera Therapeutics, Inc., acquired 2,000,000 stock options.
- The options have an exercise price of $0.022.
- The options vest in 48 equal monthly installments starting June 1, 2025.
- The options expire on April 30, 2035.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative. It reflects standard executive compensation practices.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This filing indicates a grant of stock options to a key executive.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date of transaction: Joel F. Sussman acquired 2,000,000 stock options. |
| 06/01/2025 | First vesting date: The options vest in 48 substantially equal monthly installments with the first installment vesting on this date. |
| 04/30/2035 | Expiration date: The stock options expire on this date. |
| 05/05/2025 | Date of signature. |
Keywords
stock options, Form 4, Galera Therapeutics, GRTX, insider trading, Joel F. Sussman, Chief Accounting Officer, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.